Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25733977 | 0.79 | GAA (0.34) | PYCR1HSD11B1IDO1L3MBTL1 | |
| SCHEMBL21764599 | 0.74 | PTPN7 (0.37) | PYCR1NR3C1SLC22A12AR | |
| SCHEMBL22275345 | 0.73 | NR3C1 (0.31) | NR3C1NR3C2 | |
| SCHEMBL29300177 | 0.72 | CCR2 (0.36) | PYCR1HSD11B1IDO1S1PR1 | |
| SCHEMBL22155162 | 0.72 | IDO1 (0.39) | PYCR1IDO1S1PR1 | |
| SCHEMBL19841847 | 0.71 | F2R (0.31) | — | |
| SCHEMBL26420508 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL24733156 | 0.70 | PLA2G7 (0.34) | PYCR1 | |
| SCHEMBL24065732 | 0.69 | HSD11B1 (0.36) | HSD11B1NR3C1S1PR1SLC22A12L3MBTL1 | |
| SCHEMBL24852110 | 0.68 | IDO1 (0.41) | PYCR1IDO1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | AURKA, AURKC, AURKB | PYCR1 2764/4885HSD11B1 2139/4885IDO1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.